Skip to content
Venus Remedies logo

Venus Remedies

VENUSREM NSE
₹1,380.90 +65.70 (+5.00%)
P/E
15.89
View as Markdown
MCP
Close 4 Nov 2026 ₹1,380.90 +939.15 +213% 1Y
Start ₹441.75

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
20.70%
Debt to Equity
0.02
EPS (TTM)
₹86.92
Book Value
₹527.05
Market Cap
—
P/E (TTM)
15.89
P/B
2.62
ROE
15.60%
Dividend Yield
0.76%
EBITDA
₹160 Cr
52W High
₹2,044.30
52W Low
₹436.60
Day Range
₹1,316.10 – ₹1,380.90
Volume
35,894

Peer Comparison

Healthcare › Pharmaceuticals

Venus Remedies peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Venus Remedies (this company)
₹1,380.9015.89₹1,811 Cr2.620.76%15.60%20.70%₹811 Cr₹117 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.67%16.25%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 98/100

surveillance:ASM4

Category scores

Quality
59
Good
Returns, margins, earnings quality 22% weight
Valuation
87
Strong
Cheap vs sector & own history 24% weight
Growth
70
Strong
Sales & profit trajectory 9% weight
Financial Health
71
Strong
Solvency, leverage, coverage 9% weight
Momentum
59
Good
Trend strength, vol-adjusted 12% weight
Ownership
54
Average
FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM4 ≤ 40).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has delivered good profit growth of 20.0% CAGR over last 5 years
  • Company's working capital requirements have reduced from 88.6 days to 61.9 days

Weaknesses

3
  • Stock is trading at 3.26 times its book value
  • The company has delivered a poor sales growth of 7.09% over past five years.
  • Company has a low return on equity of 9.53% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish874
OscillatorsBearish270
Moving AveragesStrong Bearish604

Key readings

RSI (14)
41.43
Neutral
MACD (12,26,9)
−89.97
Bearish
SMA (50)
1,583.52
Bearish
SMA (200)
1,292.18
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+6.53%
5Y+7.08%
3Y+11.54%
1Y+18.76%
TTM+19.44%

Net profit

Net profit growth by window
10Y+48.31%
5Y+10.69%
3Y+56.25%
1Y+128.89%
TTM+112.73%

Operating cash flow

Operating cash flow growth by window
10Y+12.75%
5Y+3.40%
3Y+61.55%
1Y+81.40%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−0.71 pp
5Y+9.26 pp
3Y+8.32 pp
1Y+8.49 pp
TTM+10.16 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹400 Cr
Mar 2018₹372 Cr
Mar 2019₹322 Cr
Mar 2020₹335 Cr
Mar 2021₹544 Cr
Mar 2022₹597 Cr
Mar 2023₹552 Cr
Mar 2024₹596 Cr
Mar 2025₹645 Cr
Mar 2026₹766 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹17.00 Cr
Mar 2018−₹31.00 Cr
Mar 2019−₹29.00 Cr
Mar 2020−₹10.00 Cr
Mar 2021₹62.00 Cr
Mar 2022₹41.00 Cr
Mar 2023₹27.00 Cr
Mar 2024₹28.00 Cr
Mar 2025₹45.00 Cr
Mar 2026₹103 Cr

Quarterly Results

₹ Cr
VENUSREM quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
95
168
143
195
109
170
177
195
137
193
180
259
179
219
Expenses
85
150
131
176
97
163
158
166
122
162
143
196
145
176
Operating Profit
10
18
12
19
11
8
18
29
15
31
38
63
34
43
OPM %
11%
11%
8%
10%
10%
4.5%
10%
15%
11%
16%
21%
24%
19%
19%
Other Income
2
3
2
4
2
8
12
7
3
2
3
5
3
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
8
6
7
6
6
6
5
5
6
6
7
7
7
10
PBT
5
14
8
17
7
9
25
31
13
26
33
62
30
33
Tax %
77%
31%
12%
40%
82%
61%
21%
32%
24%
24%
24%
23%
24%
23%
Net Profit
1
10
7
11
1
4
20
21
10
20
26
48
23
26
EPS (₹)
0.88
7.44
5.12
7.86
0.91
2.63
14.66
15.71
7.18
15.06
19.14
35.54
17.18
—

Sep 2026: from the results filed on 26 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
VENUSREM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
455
407
400
372
322
335
544
597
552
596
645
766
811
Expenses
366
326
349
333
289
295
490
535
492
537
577
619
645
Operating Profit
89
81
51
39
33
41
54
62
60
60
69
147
166
OPM %
20%
20%
13%
11%
10%
12%
10%
10%
11%
10%
11%
19%
20%
Other Income
1
2
2
2
−3
−4
43
8
10
12
26
13
12
Interest
41
38
34
35
25
13
13
0
0
0
0
0
0
Depreciation
46
42
40
34
34
32
35
34
32
26
23
26
26
PBT
3
4
−22
−28
−30
−8
49
36
38
45
72
134
152
Tax %
−95%
52%
−21%
11%
−4%
24%
−27%
−12%
30%
36%
37%
23%
—
Net Profit
5
2
−17
−31
−29
−10
62
41
27
28
45
103
116
EPS (₹)
4.51
1.49
−13.84
−24.87
−23.15
−8.1
50.05
30.46
19.88
21.31
33.9
76.9
86.92
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
13%
—

Balance Sheet

₹ Cr
VENUSREM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
11
11
12
12
12
12
12
13
13
13
13
13
Reserves
445
426
376
350
320
311
388
427
447
474
548
650
Borrowings
321
335
312
307
298
220
51
43
42
41
2
12
Other Liabilities
64
70
65
82
102
100
104
97
98
98
153
178
Total Liabilities
841
843
765
751
733
644
556
580
601
627
716
854
Fixed Assets
444
452
406
389
364
289
262
241
216
219
229
232
CWIP
78
80
66
65
65
25
25
25
26
21
26
51
Investments
0
0
0
0
0
0
0
0
20
19
84
238
Other Assets
319
310
293
297
304
330
269
314
339
368
376
333
Total Assets
841
843
765
751
733
644
556
580
601
627
716
854

Cash Flow

₹ Cr
VENUSREM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
68
47
59
31
45
78
132
41
37
37
86
156
Investing
−67
3
−18
8
−11
−5
57
−17
−58
−8
−77
−185
Financing
−1
−46
−44
−39
−35
−73
−162
−9
−1
−1
−1
−3
Net Cash Flow
−1
3
−4
0
−1
0
27
14
−22
28
9
−32
Free Cash Flow
59
46
41
19
35
70
132
41
29
24
69
118
CFO/OP
76
58
116
79
139
190
245
66
61
89
148
129

Ratios

VENUSREM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
51
55
43
46
43
33
21
24
51
49
64
49
Inventory Days
194
219
226
246
286
296
129
118
132
125
97
122
Days Payable
40
38
48
52
72
77
76
47
56
55
89
107
Cash Conversion Cycle
204
236
221
240
257
252
74
95
127
120
72
64
Working Capital Days
54
69
54
25
−1
73
71
82
109
118
86
62
ROCE %
6%
5%
2%
1%
1%
2%
8%
8%
8%
9%
11%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Venus Remedies insights

66 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 44.01%
  • Promoters 41.76%
  • Others 10.35%
  • FIIs 3.14%
  • DIIs 0.74%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Venus Remedies

What does Venus Remedies Ltd do?
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies.
Where is Venus Remedies Ltd (VENUSREM) listed?
Venus Remedies Ltd trades as VENUSREM on the NSE and under code 526953 on the BSE.
Which sector does Venus Remedies Ltd belong to?
Venus Remedies Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Venus Remedies Ltd?
Venus Remedies Ltd trades at a PE ratio of 15.89 as of 4 Nov 2026, on earnings per share of ₹86.92, against a book value of ₹527.05 per share.
What is the 52-week high and low of Venus Remedies Ltd?
Over the last 52 weeks Venus Remedies Ltd has traded between ₹436.6 and ₹2,044.3 as of 4 Nov 2026.
Does Venus Remedies Ltd pay dividends?
Venus Remedies Ltd has a dividend yield of 0.76%.
What is the Return on Equity (ROE) of Venus Remedies Ltd?
Venus Remedies Ltd reported a return on equity of 15.60%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}

Website venusremedies.com
CEO Mr. Pawan Chaudhary
Employees 1,298
Listed 20 Dec 2006
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VENUSREM.md for Venus Remedies Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month